Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.
The field of pharmacogenetics contains a wealth of potential for the enhancement of clinical practice by providing a more effective match between patient and drug, consequently reducing the probability of an adverse drug reaction. Although a relatively novel concept in the forensic context, pharmacogenetics has the capability to assist in the interpretation of drug related deaths, particularly in unintentional drug poisonings where the cause of death remains unclear. However, the complex pharmacology of the drugs when subjected to genetic variations in metabolism makes interpretation of the expected response and adverse events difficult. Many possess multiple metabolic pathways, narrow therapeutic indices and active metabolites or enantiomers which may be eliminated via different pathways to the parent drug. A number of these drugs, which are metabolised primarily by the CYP450 system, are also associated with serotonin syndrome, or serotonin toxicity, especially when used concomitantly with other serotonin active drugs which rely on the same metabolic pathways for drug elimination. A comprehensive understanding of polymorphic drug metabolism and its expected outcomes is therefore essential when interpreting the involvement of drugs in adverse reactions. This review examines the genetically variable CYP450-mediated metabolism of a number of serotonin-active drugs that are often implicated in cases of serotonin toxicity, to assess the impact of pharmacogenetics on drug metabolism, response, interactions and adverse effects.
Department of Forensic Medicine, Monash University, Victorian Institute of Forensic Medicine, Southbank, VIC, Australia. jenniferp@vifm.org
J L
JL
Pilgrim
D
D
Gerostamoulos
Olaf H
OH
Drummer
D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004347:Drug Interactions / Q000235:genetics; D005554:Forensic Medicine / Q000379:methods*; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics*; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic; D018490:Serotonin Agents / Q000009:adverse effects* / Q000493:pharmacokinetics*
D018490:Serotonin Agents; D003577:Cytochrome P-450 Enzyme System